JACC. Case reports · 2025
Severe Perivalvular Abscess After ViV-TAVR for Infective Endocarditis Following SAVR Accompanied Multiple Comorbidities.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cao Yuan, Liu Xiangjuan, Ma Lianyue, Liu Yan, An Guipeng, Wang Dandan, Meng Xiao
Аннотация
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is contraindicated in active infective endocarditis (IE). However, valve-in-valve TAVR (ViV-TAVR) may be an alternative in high-surgical-risk patients with prosthetic valve dysfunction, even with prior IE.
CASE SUMMARY: A patient developed structural valve deterioration of the bioprosthetic aortic valve 1 year after initial surgery, requiring reintervention. Comorbidities included lung cancer with bone metastasis and a history of IE. With an STS PROM of 10.2%, the patient was considered too high risk for redo sternotomy, and ViV-TAVR was pursued after 1 year of antimicrobial therapy. Postoperatively, a perivalvular abscess was found at 1 month, and the patient died 3 months later due to massive gastrointestinal bleeding.
DISCUSSION: This case illustrates the use of ViV-TAVR in a high-risk patient with prior IE. It highlights the need for intensified postoperative antibiotic therapy, even without clear signs of active infection.
TAKE-HOME MESSAGES: ViV-TAVR may be an option in high-risk patients with healed IE, provided infection resolution is clearly established. Postoperative anti-infective therapy should be optimized individually based on comorbidities and infection history. Diabetes may be a risk factor for poorer outcomes in such cases.
CASE SUMMARY: A patient developed structural valve deterioration of the bioprosthetic aortic valve 1 year after initial surgery, requiring reintervention. Comorbidities included lung cancer with bone metastasis and a history of IE. With an STS PROM of 10.2%, the patient was considered too high risk for redo sternotomy, and ViV-TAVR was pursued after 1 year of antimicrobial therapy. Postoperatively, a perivalvular abscess was found at 1 month, and the patient died 3 months later due to massive gastrointestinal bleeding.
DISCUSSION: This case illustrates the use of ViV-TAVR in a high-risk patient with prior IE. It highlights the need for intensified postoperative antibiotic therapy, even without clear signs of active infection.
TAKE-HOME MESSAGES: ViV-TAVR may be an option in high-risk patients with healed IE, provided infection resolution is clearly established. Postoperative anti-infective therapy should be optimized individually based on comorbidities and infection history. Diabetes may be a risk factor for poorer outcomes in such cases.